Eli Lilly, EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
Indianapolis: Eli Lilly and Company and EVA Pharma have announced that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. Discovered by Incyte and licensed to Lilly, baricitinib is for the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.
Accord to the release, this collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030.
"Our commitment to expanding access to affordable and innovative medicines for people living in low- to middle-income countries continues," said Ilya Yuffa, executive vice president and president of Lilly International. "Following our collaboration with EVA Pharma on insulin manufacturing, we are now establishing the first of its kind voluntary licensing agreement for Lilly, where the company will provide certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply baricitinib to people in 49 countries across Africa."
"We are proud to localize the entire value chain of this critical medication on the continent, from producing high-potency baricitinib active pharmaceutical ingredient (API), to tackling complex manufacturing challenges," said Riad Armanious, CEO of EVA Pharma.
Read also: CDSCO Panel Approves Eli Lilly's Protocol Amendment proposal to study Antidiabetic Drug Tirzepatide
EVA Pharma's high-containment facility is set to begin sales of the locally manufactured baricitinib by 2026 to various African countries.
Since 2021, EVA Pharma has been working with Lilly to ensure a sustainable supply of life-saving medicines across several African countries. Lilly and EVA Pharma are also collaborating to expand access to affordable insulin in 56 countries, most of which are low- to middle-income, as announced in 2022.
Read also: CDSCO Panel Approves Eli Lilly's Protocol Amendment proposal to study Antidiabetic Drug Tirzepatide
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.